325 related articles for article (PubMed ID: 32129935)
1. Cardiovascular immune-related adverse events: Evaluation, diagnosis and management.
Liu Y; Wu W
Asia Pac J Clin Oncol; 2020 Aug; 16(4):232-240. PubMed ID: 32129935
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicities associated with immune checkpoint inhibitors.
Yang S; Asnani A
Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
[TBL] [Abstract][Full Text] [Related]
6. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience.
Xiao J; Li X; Wang X; Guan Y; Liu H; Liang J; Li Y; Wang B; Wang J
Front Cardiovasc Med; 2023; 10():1093383. PubMed ID: 37089888
[TBL] [Abstract][Full Text] [Related]
8. Advances in immune checkpoint inhibitors induced-cardiotoxicity.
Li X; Peng W; Wu J; Yeung SJ; Yang R
Front Immunol; 2023; 14():1130438. PubMed ID: 36911712
[TBL] [Abstract][Full Text] [Related]
9. Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity.
Wang Y; Ertl C; Schmitt C; Hammann L; Kramer R; Grabmaier U; Schöberl F; Anz D; Piseddu I; Pesch G; Vera J; Froehlich W; Weckbach L; Tomsitz D; Loquai C; Zimmer L; Mangana J; Dummer R; Gutzmer R; Klespe KC; Stege H; Meiss F; Thoms KM; Terheyden P; Bröckelmann PJ; Johnson DB; French LE; Heinzerling L
Front Cardiovasc Med; 2024; 11():1408586. PubMed ID: 38915743
[TBL] [Abstract][Full Text] [Related]
10. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
Asnani A
Curr Oncol Rep; 2018 Apr; 20(6):44. PubMed ID: 29644505
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
15. Cardiac Complications in Immune Checkpoint Inhibition Therapy.
Tajiri K; Ieda M
Front Cardiovasc Med; 2019; 6():3. PubMed ID: 30729114
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
[TBL] [Abstract][Full Text] [Related]
17. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
18. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
[TBL] [Abstract][Full Text] [Related]
20. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies.
Guo CW; Alexander M; Dib Y; Lau PKH; Weppler AM; Au-Yeung G; Lee B; Khoo C; Mooney D; Joshi SB; Creati L; Sandhu S
Eur J Cancer; 2020 Jan; 124():15-24. PubMed ID: 31707280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
